Timeline of incretin therapeutics: difference between revisions
Diff·revision 2 → 3·18:53, 8 Aug 2024
Difference between revision 2 and revision 3 of Timeline of incretin therapeutics. 12 lines changed; the page grew by 742 bytes.
| Revision 2 — 15:16, 24 Jul 2024 INN_Ingrid (talk) expand §First-generation drugs 1,103 bytes ±0 | Revision 3 — 18:53, 8 Aug 2024 TirzTaxonomist (talk) reorder the analogues chronologically rather than alphabetically 1,845 bytes +742 | ||
|---|---|---|---|
| 9 | Dates are given for the events most consistently reported in the literature. Where a discovery is attributable to a series of publications rather than one, the timeline names the period rather than a single year.{{r|holst2007}} | 9 | Dates are given for the events most consistently reported in the literature. Where a discovery is attributable to a series of publications rather than one, the timeline names the period rather than a single year.{{r|holst2007}} |
| 10 | 10 | ||
| + | 11 | == Physiology == | |
| + | 12 | | Period | Event | | |
| + | 13 | |---|---| | |
| + | 14 | | 1900s–1920s | Observation that oral glucose evokes a larger insulin response than intravenous | | |
| + | 15 | | 1960s | The term ''incretin'' revived; the enteroinsular axis proposed | | |
| + | 16 | | 1970s | GIP isolated and characterised | | |
| + | 17 | | 1980s | [[Glucagon-like peptide-1]] identified as a proglucagon product and shown to be insulinotropic | | |
| + | 18 | | 1986 | Reduced [[Incretin effect]] documented in type 2 diabetes | | |
| + | 19 | | 1990s | [[Dipeptidyl peptidase-4]] identified as the enzyme inactivating both incretins | | |
| + | 20 | ||
| + | 21 | The 1986 finding is the hinge of the field: it established that the incretin axis is defective in type 2 diabetes and therefore a therapeutic target rather than only a physiological curiosity.{{r|holst2007}} | |
| + | 22 | ||
| 11 | == References == | 23 | == References == |
| 12 | {{reflist}} | 24 | {{reflist}} |